Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.36 |
| ▸ | VCP | P55072 | 4/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MELK | Q14680 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5025601 | 1.00 | LSS (0.38) | LSSPTGDR2VCPPLGPLAT | |
| SCHEMBL5024111 | 0.87 | PLG (0.35) | LSSVCPPLGPLATLMNA | |
| SCHEMBL5028495 | 0.87 | PLG (0.35) | LSSVCPPLGPLATLMNA | |
| SCHEMBL5026538 | 0.86 | TAS2R14 (0.35) | PLGPLATLMNACYP4F2CYP4A11 | |
| SCHEMBL5026543 | 0.86 | TAS2R14 (0.35) | PLGPLATLMNACYP4F2CYP4A11 | |
| SCHEMBL5026527 | 0.84 | NR1H2 (0.35) | PLGPLATLMNACYP4F2CYP4A11 | |
| SCHEMBL5026534 | 0.84 | NR1H2 (0.35) | PLGPLATLMNACYP4F2CYP4A11 | |
| SCHEMBL5025573 | 0.80 | HTT (0.51) | LSSLMNA | |
| SCHEMBL5028551 | 0.77 | LSS (0.42) | LSSLMNA | |
| SCHEMBL5024146 | 0.74 | PTGDR2 (0.41) | PTGDR2VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442791-B2 | Aminoalkylamide substituted cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1667962-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005028427-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | LSS, CYP51A1, CYP46A1 | LSS 1/4885PTGDR2 358/4885VCP 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.